Sarina Piha-Paul

Sarina Piha-Paul

UNVERIFIED PROFILE

Are you Sarina Piha-Paul?   Register this Author

Register author
Sarina Piha-Paul

Sarina Piha-Paul

Publications by authors named "Sarina Piha-Paul"

Are you Sarina Piha-Paul?   Register this Author

100Publications

3638Reads

38Profile Views

A Deep Learning Framework for Predicting Response to Therapy in Cancer.

Cell Rep 2019 Dec;29(11):3367-3373.e4

Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Str., Athens 11527, Greece; Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Athens 11527, Greece; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Manchester Cancer Research Centre, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester M20 4GJ, UK; 1st Department of Propaedeutic Internal Medicine, Medical School, Laikon Hospital, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Athens 11527, Greece. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.11.017DOI Listing
December 2019

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.

J Hematol Oncol 2019 Dec 30;12(1):145. Epub 2019 Dec 30.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0835-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937824PMC
December 2019

Factors affecting symptom presentation in an early-phase clinical trials clinic patient population.

Invest New Drugs 2019 Nov 25. Epub 2019 Nov 25.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-019-00879-0DOI Listing
November 2019

HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.

Hum Pathol 2019 Oct 24;92:32-38. Epub 2019 Jul 24.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.07.006DOI Listing
October 2019

Vandetanib photoinduced cutaneous toxicities.

Cutis 2019 May;103(5):E24-E29

Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, and Department of Dermatology, University of Texas Medical School, Houston, USA.

View Article

Download full-text PDF

Source
May 2019

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

Gynecol Oncol 2019 02 3;152(2):243-250. Epub 2018 Dec 3.

Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.017DOI Listing
February 2019

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.

JCO Clin Cancer Inform 2018 12;2:1-14

Goldy C. George, Adrianna Buford, Kenneth Hess, Sarina A. Piha-Paul, Ralph Zinner, Vivek Subbiah, Christina Hinojosa, Charles S. Cleeland, Funda Meric-Bernstam, and David S. Hong, The University of Texas MD Anderson Cancer Center; and Elmer V. Bernstam, The University of Texas School of Biomedical Informatics, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874009PMC
December 2018

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Cancer Chemother Pharmacol 2018 11 4;82(5):877-885. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3680-yDOI Listing
November 2018

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Oncotarget 2018 Sep 4;9(69):33232-33243. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145698PMC
September 2018

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Br J Cancer 2018 04 19;118(8):1042-1050. Epub 2018 Mar 19.

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 455, Faculty Center 8th Floor, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0020-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931107PMC
April 2018

Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

J Clin Oncol 2018 01 8;36(1):61-67. Epub 2017 Nov 8.

Toshihiko Doi, National Cancer Center East, Chiba, Japan; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Shadia I. Jalal, Indiana University School of Medicine, Indianapolis, IN; Sanatan Saraf, Jared Lunceford, and Minori Koshiji, Merck, Kenilworth, NJ; and Jaafar Bennouna, Institut de Cancérologie de l'Ouest, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.9846DOI Listing
January 2018

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

J Clin Oncol 2017 Dec 2;35(36):4035-4041. Epub 2017 Nov 2.

Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.5471DOI Listing
December 2017

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

J Immunother Cancer 2017 12 19;5(1):100. Epub 2017 Dec 19.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Unit 455, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0301-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735899PMC
December 2017

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Invest New Drugs 2017 10 13;35(5):616-626. Epub 2017 Feb 13.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-017-0442-3
Publisher Site
http://dx.doi.org/10.1007/s10637-017-0442-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935457PMC
October 2017

Clinical Use of Precision Oncology Decision Support.

JCO Precis Oncol 2017 13;2017. Epub 2017 Sep 13.

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179148PMC
September 2017

Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case.

Am J Dermatopathol 2016 Nov;38(11):852-856

Departments of *Investigational Cancer Therapeutics, †Pathology, and ‡Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000604DOI Listing
November 2016

A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer.

Gynecol Oncol Rep 2016 Aug 21;17:49-52. Epub 2016 May 21.

Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2016.05.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910296PMC
August 2016

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

J Clin Oncol 2016 05 4;34(15):1764-71. Epub 2016 Apr 4.

David Hong, Filip Janku, Ly M. Nguyen, Aung Naing, Sarina Piha-Paul, Faye M. Johnson, and Razelle Kurzrock, The University of Texas MD Anderson Cancer Center, Houston, TX; Jeffrey Infante, Suzanne Jones, Howard Burris, Todd M. Bauer, and Johanna Bendell, Sarah Cannon Research Institute; Jeffrey Infante, Howard Burris, Todd M. Bauer, and Johanna Bendell, Tennessee Oncology, Nashville, TN; and Lisa Golden, Scott Hynes, Ji Lin, and Aimee Bence Lin, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.5788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321045PMC
May 2016

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 05 16;77(5):1097-102. Epub 2016 Apr 16.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3000-3DOI Listing
May 2016

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 Mar 29;77(3):575-81. Epub 2016 Jan 29.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2952-zDOI Listing
March 2016

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.

Clin Cancer Res 2015 Dec 17;21(23):5235-44. Epub 2015 Jul 17.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0180DOI Listing
December 2015

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Invest New Drugs 2015 Aug 21;33(4):911-20. Epub 2015 May 21.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0251-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0251-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492845PMC
August 2015

A decision support framework for genomically informed investigational cancer therapy.

J Natl Cancer Inst 2015 Jul 11;107(7). Epub 2015 Apr 11.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy , the University of Texas MD Anderson Cancer Center, Houston, TX (FMB, AJ, VH, AMB, JZ, KRS, JM, GBM); Departments of Investigational Cancer Therapeutics (FMB, LB, SAPP, DSH, AMT), Surgical Oncology (FMB), Hematopathology (MR, KPP), Bioinformatics & Computational Biology (KC), GI Medical Oncology (SK), Melanoma Medical Oncology (MAD), Experimental Therapeutics (RB), Systems Biology (AKE, GBM), the University of Texas MD Anderson Cancer Center, Houston, TX; School of Biomedical Informatics, the University of Texas Health Science Center, Houston, TX (EVB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/7/djv098.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv098
Publisher Site
http://dx.doi.org/10.1093/jnci/djv098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651038PMC
July 2015

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.

Invest New Drugs 2015 Jun 31;33(3):621-31. Epub 2015 Mar 31.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, MD Anderson Cancer Center, Unit 455, P.O. Box 301402, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-015-0226
Web Search
http://link.springer.com/10.1007/s10637-015-0226-6
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0226-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482235PMC
June 2015

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

J Natl Cancer Inst 2015 Mar 16;107(3). Epub 2015 Feb 16.

Departments of Breast Medical Oncology (AMGA, SL, SMT), Systems Biology (AMGA, GBM), Biostatistics (HC, YL, K-AD), Experimental Therapeutics (KSC), Investigational Cancer Therapeutics (AA, ET, SPP, VV-B, FMB), Pathology (AAS) and Surgical Oncology (FMB), The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Hematology-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (IK, EPW); Division of Hematology-Oncology, University of California, San Diego, CA (RK); Cancer Therapy Evaluation Program, NIH/National Cancer Institute, Rockville, MD (LAD).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/dju493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342675PMC
March 2015

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Invest New Drugs 2015 Feb 18;33(1):177-86. Epub 2014 Oct 18.

Sarah Cannon Research Institute at HealthONE, Presbyterian/St. Luke's Medical Center, 1800 Williams Street, Suite 300, Denver, CO, 80218, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0173-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297242PMC
February 2015

Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.

BMC Dermatol 2015 Feb 13;15. Epub 2015 Feb 13.

Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://bmcdermatol.biomedcentral.com/articles/10.1186/s12895
Publisher Site
http://dx.doi.org/10.1186/s12895-015-0022-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336708PMC
February 2015